HUTCHMED (China) Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for cancer and immunological diseases in the People’s Republic of China and Hong Kong. The company provides research and development services; and develops, manufactures, distributes, markets, and sells prescription pharmaceutical products Its clinical stage drugs include Savolitinib, a MET inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. Surufatinib, an inhibitor for the treatment of neuroendocrine tumors and solid tumors; and HMPL-523 for the treatment of hematological cancer and immunological diseases; HMPL-689 for the treatment of hematological cancer; HMPL-453 for the treatment of solid tumors; and HMPL-306 for the treatment of hematological malignancies, gliomas, and solid tumors, as well as epitinib and theliatinib, an EGFR inhibitor to penetrate the blood-brain barrier. Hutchison China MediTech Limited was founded in 2000 and is headquartered in Hong Kong, China.